Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

Kythera Biopharmaceuticals Company Profile (NASDAQ:KYTH)

Consensus Ratings for Kythera Biopharmaceuticals (NASDAQ:KYTH) (?)
Ratings Breakdown: 1 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $59.00 (64.94% upside)

Analysts' Ratings History for Kythera Biopharmaceuticals (NASDAQ:KYTH)
Show:
DateFirmActionRatingPrice TargetDetailsShare
11/11/2014FBR Capital MarketsLower Price TargetOutperform$62.00 -> $59.00ViewTweet This Rating  Share This Rating on StockTwits
10/30/2013FBR & CoInitiated CoverageOutperformViewTweet This Rating  Share This Rating on StockTwits
10/30/2013FBR Capital MarketsInitiated CoverageOutperform$58.00ViewTweet This Rating  Share This Rating on StockTwits
10/25/2013Bank of AmericaInitiated CoverageBuyViewTweet This Rating  Share This Rating on StockTwits
9/17/2013JPMorgan Chase & Co.Boost Price TargetOverweight$34.00 -> $45.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2013Cowen and CompanyReiterated RatingBuy$50.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2013Leerink SwannBoost Price Target$34.00 -> $50.00ViewTweet This Rating  Share This Rating on StockTwits
9/17/2013Goldman SachsInitiated CoverageNeutral$37.00ViewTweet This Rating  Share This Rating on StockTwits
9/6/2013Cowen and CompanyInitiated CoverageOutperform$50.00ViewTweet This Rating  Share This Rating on StockTwits
8/7/2013Leerink SwannBoost Price Target$28.00 -> $34.00ViewTweet This Rating  Share This Rating on StockTwits
8/7/2013JPMorgan Chase & Co.Boost Price Target$30.00 -> $34.00ViewTweet This Rating  Share This Rating on StockTwits
5/14/2013Lazard LtdLower Price TargetBuy$33.00 -> $32.00ViewTweet This Rating  Share This Rating on StockTwits
5/4/2013Ativo ResearchInitiated CoverageMost UnfavorableViewTweet This Rating  Share This Rating on StockTwits
(Data available from 11/23/2012 forward)